---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Hypoglossal nerve stimulation"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Hypoglossal nerve stimulation. Topics: VA/DoD 2025 recommendation for referral after unsuccessful positive airway pressure therapy, FDA device criteria as summarized in the VA/DoD 2025 guideline, Procedure-related and study-related adverse events, ERS 2021 recommendation: salvage treatment rather than first-line treatment, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/hypoglossal-nerve-stimulation"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Hypoglossal nerve stimulation

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Hypoglossal Nerve Stimulation

<a id="topic-2.2.2.1.5-1"></a>

### VA/DoD 2025 recommendation for referral after unsuccessful positive airway pressure therapy

> “For treatment of obstructive sleep apnea in appropriate* patients (including with an apnea hypopnea index of 15 or greater per hour) who have not been successful with positive airway pressure therapy, we suggest referral for evaluation for hypoglossal nerve stimulation therapy.”
> “Evidence suggests that HGNS improves the apnea-hypopnea index (AHI), oxygen desaturation index (ODI), excessive daytime sleepiness, and health-related quality of life (QoL) in patients with OSA who have not been successfully treated with PAP.”
> “Although our evidence review did not include studies of MAD, clinicians may consider a trial of PAP as well as MAD prior to surgical referral.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### FDA device criteria as summarized in the VA/DoD 2025 guideline

> “HGNS uses an implanted neurostimulator that dilates the upper airway by selectively stimulating branches of the hypoglossal nerve, predominantly innervating the genioglossus muscle, while the device is active during sleep”
> “and a diagnosis of moderate to severe OSA with AHI 15-100 events per hour who have failed or are intolerant to PAP therapy.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Procedure-related and study-related adverse events

> “The published rates of serious adverse events from surgical implantation and device use are low (196), although one RCT (n=138 patients) reported that 72.5% of patients experienced a total of 164 procedure or study-related adverse events.(195)”
> “The most common non-serious procedure-related adverse events were wound healing (e.g., erythema, seroma; 15.2% patients), temporary incisional numbness (13.8% patients), and post-op discomfort related to incisions (12.3% patients), and the most common non-serious study-related adverse event was discomfort due to stimulation (33% of patients).(195)”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### ERS 2021 recommendation: salvage treatment rather than first-line treatment

> “We suggest that HNS should not be used as first-line treatment for OSA patients in general (conditional recommendation, very low quality of evidence). However, we suggest that HNS compared to no treatment should be considered as a salvage treatment in patients with symptomatic OSA, who cannot be sufficiently treated with positive airway pressure treatment (CPAP, bilevel positive airway pressure) or MAD, and who have an AHI <50 events·h−1 and a BMI <32 kg·m−2 (conditional recommendation, very low quality of evidence) (supplementary table e13).”
> “There is limited evidence available for this intervention; a general recommendation was based on selected patients from three RCTs with very strict patient selection (only ∼10% of the screened patients were included) [20, 52, 53].”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="topic-2.2.2.1.5-5"></a>

### STAR trial: eligibility and twelve-month outcomes, AHI scored by a core laboratory with standard criteria

> “Participants with moderate-to-severe obstructive sleep apnea were eligible for enrollment if they had difficulty accepting or adhering to CPAP treatment.”
> “The primary outcome measures were assessed by means of overnight polysomnography and scored by an independent core laboratory with the use of standard criteria.”
> “The median AHI score decreased 68%, from the baseline value of 29.3 events per hour to 9.0 events per hour. The median ODI score decreased 70%, from 25.4 events per hour to 7.4 events per hour.”
> “At the 12-month visit, the criteria for the coprimary outcome of a reduction of at least 50% in the AHI score from baseline and an AHI score of less than 20 events per hour were met by 66% of the participants (83 of 126 participants; lower boundary of the 97.5% confidence interval [CI], 57).”
> “The rate of procedure-related serious adverse events was less than 2%.”

Source: [Strollo et al. (2014)](https://www.nejm.org/doi/full/10.1056/NEJMoa1308659)

<a id="topic-2.2.2.1.5-6"></a>

### STAR trial: five-year outcomes

> “From a cohort of 126 patients, 97 completed protocol, and 71 consented to a voluntary polysomnogram.”
> “AHI response rate (AHI <20 events per hour and >50% reduction) was 75% (n = 71). When a last observation carried forward analysis was applied, the responder rate was 63% at 5 years. Serious device-related events all related to lead/device adjustments were reported in 6% of patients.”

Source: [Woodson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29582703/)

<a id="topic-2.2.2.1.5-7"></a>

### Manufacturer description of hypoglossal nerve stimulation as an alternative

> “A surgically implanted hypoglossal nerve stimulator can be an option for some patients with moderate to severe OSA who fail PAP.”
> “Additionally, only approximately 100,000 patients have received this treatment over the lifetime of its availability as of March 2025.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
